FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

D

I

OMB Number:	3235-0287					
Estimated average burden						
hours per response:	0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Add <u>Clemmer Ja</u>	dress of Reporting ames <u>C</u>	Person [*]		ier Name and Ticke GIODYNAM					ationship of Reportin all applicable) Director	10% C	Owner	
(Last) 14 PLAZA DI	(First) RIVE	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 07/07/2022						Officer (give title below) Presiden	Other below t and CEO	(specify)
(Street)			4. If Ar	4. If Amendment, Date of Original Filed (Month/Day/Year)						vidual or Joint/Group	Filing (Check A	pplicable
LATHAM	NY	12110								Form filed by One Reporting Person		
(City)	(State)	(Zip)								Form filed by Mor Person	re than One Rep	orting
		Table I - Nor	n-Derivative S	Securities Acq	uired	, Dis	posed of, c	or Ben	eficially	Owned		
Date			2. Transaction Date (Month/Day/Year)	Execution Date, Transaction Disposed Of (D) (Instr. 3, 4				and 5) Securities F Beneficially (I Owned Following (I		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(1150.4)

								·				, 			
Common Stock				7/2022		F	8,	574 ⁽²⁾	D	\$20.54	407	,313	D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative	2. Conversion	3. Transaction Date	3A. Deemed Execution Date,	4. Transactio			Exercisable ion Date		. Title and f Securitie		8. Price of Derivative				11. Nature of Indirect

M 25,123⁽¹⁾ A **\$**0

Derivative Security Instr. 3)	Conversion or Exercise Price of Derivative Security	(Month/Day/Year)	SA. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Deri Secu Acq (A) o Disp of (E	vative urities uired or oosed D) (Instr. and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		e of Securities ar) Underlying		Derivative Security (Instr. 5)	derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
 Performance Right	(3)	07/07/2022		М			50,139	(3)	(3)	Common Stock	50,139	\$ <mark>0</mark>	0	D		

Explanation of Responses:

Common Stock

1. This acquisition of 25,123 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on October 16, 2019

2. The exempt disposition of 8,574 shares of Common Stock to the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on October 16, 2019.

3. On October 16, 2019, the reporting person received a target grant of 50,139 performance share units. Between 0% and 200% of the target number was to be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Based on performance over the period, 25,123 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

/s/ Richard C.Rosenzweig, as	07/08/2022
Attorney in Fact	07/08/2022

Date

415,887

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

07/07/2022

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.